Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christina Muller

Nurse Practitioner, Acute Care Wooster, OH Nurse Practitioner

NPI 1154762235 CMS profile 10559841

1761 Beall Ave Ste 101, Wooster, OH 44691

Open in the dashboard

General payments

$4,938

228 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Muller of Wooster, OH is reported in the CMS Open Payments database as having received $4,938 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $691 34
2024 General $1,106 50
2023 General $1,336 59
2022 General $872 39
2021 General $932 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Muller
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Christina Muller were reported at $691. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Christina Muller Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $932 $123 $38–$327 $132
2022 $872 $130 $44–$369 $149
2023 $1,336 $144 $49–$410 $160
2024 $1,106 $146 $48–$433 $164
2025 $691 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $871 37 payments
  2. GlaxoSmithKline, LLC. $505 43 payments
  3. Inspire Medical Systems, Inc. $384 5 payments
  4. Genzyme Corporation $360 16 payments
  5. Regeneron Healthcare Solutions, Inc. $337 13 payments
  6. AbbVie, Inc. $290 3 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $284 15 payments
  8. Electromed, Inc. $188 15 payments
  9. Sanofi-Aventis U.S. LLC $188 2 payments
  10. Actelion Pharmaceuticals US, Inc. $163 8 payments
  11. Other $1,368 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,750 226 payments
  2. Education $188 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $564 19 payments
  2. FASENRA $420 15 payments
  3. INSPIRE $384 5 payments
  4. TEZSPIRE $307 8 payments
  5. BREZTRI $304 9 payments
  6. DUPIXENT Inflammation And Immunology $257 10 payments
  7. TRELEGY ELLIPTA $256 23 payments
  8. NUCALA $249 20 payments
  9. SMARTVEST $188 15 payments
  10. UBRELVY $180 2 payments
  11. Other $2,735 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

3,693

Median for Nurse Practitioner: 389

Drug cost

$1,424,693

Median for Nurse Practitioner: $21,885

Branded share of claims

72.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 523 $430,826
Ofev Nintedanib Esylate Brand 11 $154,586
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 185 $153,663
Spiriva Respimat Tiotropium Bromide Brand 132 $105,732
Pirfenidone Generic 20 $96,187
Breo Ellipta Fluticasone/Vilanterol Brand 132 $86,493
Symbicort Budesonide/Formoterol Fumarate Brand 155 $59,741
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 81 $51,520
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 84 $51,207
Advair Hfa Fluticasone Propion/Salmeterol Brand 56 $43,250

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$50,288

Of which drugs: $1,973

Medicare patients

410

Average age 73

Services billed

720

211 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
COPD 50%
Ischemic heart disease 38%
Diabetes 32%
Chronic kidney disease 28%
Atrial fibrillation 27%
Heart failure 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 12 12 $982
Influenza vaccine, trivalent derived from cell cultures 90661 Office 13 13 $469

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $99
  • GENZYME CORPORATION $96
  • Regeneron Healthcare Solutions, Inc. $35
$231 — —
VRAYLAR
  • AbbVie, Inc. $110
$110 — —
NUCALA
  • GlaxoSmithKline, LLC. $92
$92 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $69
  • Amgen Inc. $15
$84 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record